By the
Numbers

4,900

Endo has approximately 4,900 employees worldwide

$4.01 Billion

Endo total 2016 revenue was $4.01 billion

250

U.S. Generic Pharmaceuticals has a portfolio of over 250 product families

200

U.S. Generic Pharmaceuticals has over 200 products in our pipeline including approximately 120 ANDAs currently under review with the FDA

20

U.S. Generics launched approximately 20 new products in 2016 including first-to-file quetiapine ER and ezetimibe tablets

+18%

U.S. Specialty Branded Pharmaceuticals performance +18% in 2016

$190 Million

XIAFLEX® achieved US sales of $190 million, a 20% increase vs. prior year

30 Million

Endo pursuing an indication for cellulite after XIAFLEX® demonstrated a highly statistically significant Ph2b data in cellulite; approximately 30 million women identified with self‐reported cellulite